Filings & corporate actions
- 2 NovresultsResults · Q2 FY27 · standalone+0.5%NSE
- 16 OctshareholdingShareholding · 30 Sept 2026+1.0%NSE
- 27 AugdividendDividend · ₹45.00 per share-0.8%
- 6 AugresultsResults · Q1 FY27 · standalone+1.3%NSE
- 3 JulshareholdingShareholding · 30 Jun 2026-1.8%NSE
- 27 MayresultsResults · Q4 FY26 · standalone-3.1%NSE
- 26 MayresultsResults · Q4 FY26 · standalone+10.5%NSE
- 20 AprshareholdingShareholding · 31 Mar 2026+1.3%NSE
- 12 FebdividendDividend · ₹160.00 per share-5.7%
- 6 FebresultsResults · Q3 FY26 · standalone+3.7%NSE
- 21 JanshareholdingShareholding · 31 Dec 2025-0.7%NSE
Reaction to results · all yearsrose on day 0 in 40 of 76 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q2 FY27 | 2 Nov 2026 | +0.5% | -2.2% | — | 1.9× |
| Q1 FY27 | 6 Aug 2026 | +1.3% | -2.2% | -6.7% | 1.1× |
| Q4 FY26 | 26 May 2026 | +10.5% | +9.7% | +10.3% | 29.2× |
| Q3 FY26 | 6 Feb 2026 | +3.7% | -2.6% | -5.7% | 3.5× |
| Q2 FY26 | 5 Nov 2025 | -1.1% | -3.5% | -3.5% | 2.9× |
| Q1 FY26 | 1 Aug 2025 | +1.1% | +2.0% | +1.6% | 2.3× |
| Q4 FY25 | 17 Jun 2025 | +0.7% | -0.1% | -1.0% | 0.6× |
| Q3 FY25 | 12 Feb 2025 | -1.1% | -0.4% | -4.0% | 2.9× |
| Q2 FY25 | 4 Nov 2024 | +4.9% | +2.1% | +5.9% | 28.6× |
| Q1 FY25 | 22 Aug 2024 | -2.5% | -3.1% | -5.1% | 4.1× |
| Q4 FY24 | 3 May 2024 | -1.3% | -2.2% | -2.4% | 3.5× |
| Q3 FY24 | 7 Feb 2024 | +2.4% | -4.8% | -4.9% | 1.1× |
| Q2 FY24 | 4 Nov 2023 | -0.8% | +1.2% | -0.2% | 1.1× |
| Q1 FY24 | 24 Aug 2023 | -4.8% | -8.8% | -9.0% | 5.2× |
| Q4 FY23 | 16 May 2023 | +3.1% | +7.6% | +7.9% | 2.6× |
| Q3 FY23 | 6 Feb 2023 | +14.6% | +14.3% | +24.0% | 40.6× |
| Q2 FY23 | 12 Nov 2022 | +3.2% | +0.3% | -1.0% | 2.8× |
| Q1 FY23 | 30 Aug 2022 | +0.9% | +3.2% | -4.9% | 2.1× |
| Q4 FY22 | 6 May 2022 | -2.9% | -2.4% | -2.2% | 1.2× |
| Q3 FY22 | 9 Feb 2022 | -1.2% | -7.2% | -12.5% | 1.3× |
| Q2 FY22 | 9 Nov 2021 | -0.9% | -5.8% | -1.9% | 0.7× |
| Q1 FY22 | 27 Aug 2021 | -0.9% | -3.8% | -2.7% | 1.1× |
| Q4 FY21 | 6 May 2021 | -6.6% | -7.0% | -7.2% | 8.2× |
| Q3 FY21 | 11 Feb 2021 | +0.8% | -3.7% | -10.5% | 1.6× |
| Q2 FY21 | 12 Nov 2020 | +5.4% | +12.0% | +24.2% | 4.4× |
| Q3 FY20 | 4 Mar 2020 | -0.7% | -9.6% | -3.9% | 1.3× |
| Q2 FY20 | 8 Nov 2019 | -6.4% | -6.4% | -8.4% | 3.6× |
| Q1 FY20 | 9 Aug 2019 | +0.2% | -4.9% | -7.1% | 1.3× |
| Q4 FY19 | 10 May 2019 | +5.2% | +22.5% | +7.6% | 8.3× |
| Q3 FY19 | 7 Mar 2019 | -1.4% | -2.5% | +10.1% | 0.8× |
| Q2 FY19 | 9 Nov 2018 | -2.0% | +0.3% | -6.0% | 0.8× |
| Q1 FY19 | 20 Aug 2018 | +4.7% | +11.5% | +5.3% | 0.5× |
| Q4 FY18 | 18 Jun 2018 | +1.9% | +4.3% | -3.6% | 0.2× |
| Q3 FY17 | 26 Feb 2018 | +0.6% | +0.7% | +0.8% | 0.5× |
| Q3 FY18 | 26 Feb 2018 | +0.6% | +0.7% | +0.8% | 0.5× |
| Q2 FY18 | 22 Nov 2017 | +0.1% | -0.9% | +9.2% | 1.8× |
| Q4 FY17 | 12 Oct 2017 | +1.7% | +14.1% | +8.1% | 0.7× |
| Q1 FY18 | 2 Sept 2017 | +1.2% | -4.0% | -12.9% | 0.6× |
| Q2 FY17 | 17 Nov 2016 | +4.6% | +8.1% | +20.2% | 2.5× |
| Q1 FY17 | 21 Sept 2016 | +0.2% | -4.2% | +16.3% | 1.6× |
| Q3 FY16 | 25 May 2016 | +0.2% | +1.8% | -1.7% | 0.4× |
| Q4 FY16 | 16 May 2016 | +6.3% | +3.1% | +3.7% | 18.6× |
| Q2 FY16 | 31 Oct 2015 | -2.2% | -2.3% | +0.3% | 1.8× |
| Q1 FY16 | 16 Aug 2015 | -1.0% | -7.8% | -10.0% | 0.4× |
| Q4 FY15 | 9 May 2015 | +0.4% | +1.1% | -5.2% | 0.4× |
| Q3 FY15 | 6 Feb 2015 | -0.9% | -2.1% | +3.7% | 0.6× |
| Q2 FY15 | 21 Nov 2014 | -1.4% | -2.2% | +2.0% | 0.7× |
| Q1 FY15 | 19 Aug 2014 | -1.0% | -3.9% | +0.4% | 0.4× |
| Q4 FY14 | 5 May 2014 | -0.9% | -3.2% | -2.0% | 0.4× |
| Q3 FY14 | 1 Feb 2014 | -1.8% | -2.6% | +5.1% | 0.7× |
| Q2 FY14 | 21 Oct 2013 | -2.2% | -1.7% | -1.5% | 0.9× |
| Q1 FY14 | 5 Aug 2013 | -0.8% | +4.6% | -2.7% | 0.3× |
| Q4 FY13 | 9 May 2013 | +1.3% | +1.3% | +2.3% | 1.4× |
| Q3 FY13 | 28 Feb 2013 | -0.5% | -0.8% | -0.6% | 0.9× |
| Q2 FY13 | 1 Nov 2012 | 0.0% | -1.4% | +2.3% | 0.6× |
| Q1 FY13 | 27 Jul 2012 | +1.0% | +1.7% | +1.2% | 2.0× |
| Q4 FY12 | 7 May 2012 | +0.4% | -2.2% | -6.5% | 0.1× |
| Q3 FY12 | 29 Feb 2012 | -2.1% | -3.9% | -5.3% | 1.9× |
| Q2 FY12 | 1 Nov 2011 | -1.9% | -0.4% | -6.4% | 2.7× |
| Q1 FY12 | 27 Jul 2011 | -1.3% | -2.4% | -10.7% | 0.4× |
| Q4 FY11 | 25 Apr 2011 | -0.7% | -6.8% | -9.6% | 5.1× |
| Q2 FY11 | 20 Oct 2010 | +20.0% | +2.9% | +0.3% | 79.0× |
| Q1 FY11 | 29 Jul 2010 | +0.9% | -0.1% | -1.4% | 2.7× |
| Q4 FY10 | 23 Apr 2010 | -0.8% | -6.6% | -5.3% | 1.1× |
| Q3 FY10 | 22 Jan 2010 | -2.3% | -4.3% | -1.6% | 0.5× |
| Q2 FY10 | 15 Oct 2009 | +17.1% | +30.8% | +33.9% | 42.0× |
| Q1 FY10 | 20 Jul 2009 | +0.3% | -0.2% | +0.1% | 0.9× |
| Q4 FY09 | 20 Apr 2009 | +1.0% | -0.3% | +12.7% | 7.5× |
| Q3 FY09 | 27 Feb 2009 | -2.3% | -4.0% | +14.1% | 4.5× |
| Q2 FY09 | 30 Oct 2008 | +0.8% | +10.9% | +0.6% | 0.5× |
| Q1 FY09 | 30 Jul 2008 | +1.9% | +4.4% | +7.6% | 3.1× |
| Q4 FY08 | 16 Apr 2008 | +0.7% | +3.7% | +6.5% | 1.5× |
| Q3 FY08 | 1 Feb 2008 | +1.4% | -0.4% | -0.5% | 1.0× |
| Q2 FY08 | 18 Oct 2007 | — | — | — | — |
| Q1 FY08 | 16 Jul 2007 | — | — | — | — |
| Q4 FY07 | 20 Apr 2007 | — | — | — | — |
| Average | +0.9% | +0.4% | +0.7% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q2 FY27
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | +13.4% | +6.4% | +7.0% | +7.9% | — | +7.6% |
| Profit | +32.1% | +18.0% | +17.3% | +17.0% | — | -10.7% |
Key data
Delivery percentage
Over the last 20 sessions PGHL settled 51.8% of its traded quantity, which is above average for an NSE equity. Its one-year average is 59.0%, so recent sessions are running 7.2 points lower than usual. The latest session ranks higher than 41% of the 3,629 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
Dividends, deals & holders
Performance returns
| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +0.96% | -3.78% | +10.41% | -4.17% | +2.47% | -5.10% |
Valuation
Ownership
Quarterly results · standalone
| Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 373.9 | 370.5 | 363.7 | 382.5 |
| YoY chg | +20.7% | +19.1% | +7.4% | +17.7% |
| Net profit (₹ Cr) | 77.6 | 94.6 | 96.2 | 111.5 |
| YoY chg | -14.6% | +54.6% | +45.3% | +25.9% |
| Net margin | 20.8% | 25.5% | 26.4% | 29.2% |
| EPS | 46.74 | 56.99 | 57.92 | 67.18 |
Shareholding over time
By quarter
30 Sept 2026 · promoter 51.82% · public 48.18%- Promoter
- Public and others
- Promoter
- 51.82%
- Public
- 48.18%
- Promoter change
- 0.00 pp
- Filed
- 16 Oct 2026
- FII
- 6.42%
- DII
- 12.63%
- Promoter pledged
- 0.00%
Who the public is
- Mutual funds
- 8.89%
- Insurance
- 3.63%
- FPI
- 6.43%
- Retail ≤ ₹2L
- 21.54%
- HNI > ₹2L
- 1.81%
- NRI
- 2.42%
- Bodies corporate
- 2.40%
- Shareholders
- 50,426
-0.16 pp QoQ
+0.40 pp QoQ
+0.10 pp QoQ
-0.06 pp QoQ
-0.15 pp QoQ
-0.09 pp QoQ
+0.01 pp QoQ
+2.8% QoQ
Major holders
As of 30 Sept 2026| Holder | Type | Holding | Shares |
|---|---|---|---|
| PROCTER AND GAMBLE OVERSEAS INDIA B.V. | Promoter · Corporate | 51.82% | 86.01L |
| NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA SMA | Mutual fund | 4.18% | 6.95L |
| LIFE INSURANCE CORPORATION OF INDIA | Insurance | 1.87% | 3.11L |
| UTI-MNC FUND | Mutual fund | 1.45% | 2.40L |
| ADITYA BIRLA SUN LIFE MUTUAL FUND - ADITYA BIRLA S | Mutual fund | 1.22% | 2.03L |
Every promoter-group member, and each public holder above 1%, as filed.
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional, pledge and public-breakdown figures come from the filing's XBRL, which most filings before Sep-2021 lack, so they are absent there rather than zero. Changes are against the previous filing.
Dividends
| Financial year | Payments | Declared | Adjusted |
|---|---|---|---|
| FY2026-27 | 1 | ₹45.00 | ₹45.00 |
| FY2025-26 | 2 | ₹205.00 | ₹205.00 |
| FY2024-25 | 2 | ₹140.00 | ₹140.00 |
| FY2023-24 | 2 | ₹250.00 | ₹250.00 |
| FY2022-23 | 3 | ₹97.50 | ₹97.50 |
| FY2021-22 | 1 | ₹130.00 | ₹130.00 |
| FY2020-21 | 1 | ₹230.00 | ₹230.00 |
| FY2019-20 | 1 | ₹440.00 | ₹440.00 |
| FY2018-19 | 1 | ₹15.00 | ₹15.00 |
| FY2017-18 | 1 | ₹11.00 | ₹11.00 |
| FY2016-17 | 1 | ₹7.50 | ₹7.50 |
| FY2014-15 | 1 | ₹6.00 | ₹6.00 |
| FY2013-14 | 1 | ₹8.50 | ₹8.50 |
| FY2012-13 | 1 | ₹2.50 | ₹2.50 |
| Ex-date | Record date | Declared | Adjusted |
|---|---|---|---|
| 27 Aug 2026 | — | ₹45.00 | ₹45.00 |
| 12 Feb 2026 | — | ₹160.00 | ₹160.00 |
| 22 Aug 2025 | — | ₹45.00 | ₹45.00 |
| 21 Feb 2025 | — | ₹80.00 | ₹80.00 |
| 28 Nov 2024 | — | ₹60.00 | ₹60.00 |
| 14 Feb 2024 | — | ₹200.00 | ₹200.00 |
| 23 Nov 2023 | — | ₹50.00 | ₹50.00 |
| 13 Feb 2023 | — | ₹45.00 | ₹45.00 |
| 15 Nov 2022 | — | ₹11.50 | ₹11.50 |
| 12 May 2022 | — | ₹41.00 | ₹41.00 |
| 2 Nov 2021 | — | ₹130.00 | ₹130.00 |
| 18 Nov 2020 | — | ₹230.00 | ₹230.00 |
| 23 May 2019 | — | ₹440.00 | ₹440.00 |
| 21 May 2018 | — | ₹15.00 | ₹15.00 |
| 25 May 2017 | — | ₹11.00 | ₹11.00 |
| 22 Apr 2016 | — | ₹7.50 | ₹7.50 |
| 30 Mar 2015 | — | ₹6.00 | ₹6.00 |
| 10 Mar 2014 | — | ₹8.50 | ₹8.50 |
| 7 Mar 2013 | — | ₹2.50 | ₹2.50 |
Rupees per share by ex-date, from NSE’s corporate actions; the record date is who was paid. Declared is the figure in the filing; adjusted restates it for splits and bonuses since, on the same basis as the price chart. Financial years run April to March.
Book closures & record dates
NSE's corporate-action calendar: who held the stock on the record date, or through the book-closure window, was entitled to the dividend, bonus, split or rights named.
Insider trades
- Insiders net, 30d
- ₹0
- Insiders net, 90d
- ₹0
- Promoters net, 90d
- ₹0
- Insider buyers, 90d
- 0
- Last promoter buy
- none on record
- Disclosures on record
- 4
No open-market insider trades among the recent disclosures.
SEBI insider-trading disclosures, equity only. Dated by the day NSE broadcast them; the trade itself is often weeks earlier. The figures count promoters, directors and KMPs buying or selling on the exchange — not ESOPs, gifts, transfers within the promoter group or pledges. Stake is the holding after, as filed; the change beneath it scales that by the share counts before and after. Regulation is the PIT clause cited, and “told” the day the insider informed the company.
How the insider figures are countedPromoters buying in the open market, market-wideEvery stock on this session
Bulk & block deals · 3 Oct 2022
CSV| Date | Deal | Client | Quantity | Price | Value |
|---|---|---|---|---|---|
| 3 Oct 2022 | Sell · block | ISHARES CORE EMERGING MARKETS MAURITIUS CO | 44.7K | 4,106.95 | ₹18.4Cr |
| 3 Oct 2022 | Buy · block | ISHARES CORE MSCI EMERGING MARKETS ETF | 44.7K | 4,106.95 | ₹18.4Cr |
| 3 Oct 2022 | Sell · block | ISHARES INDIA SC MAURITIUS COMPANY | 6.4K | 4,106.95 | ₹2.6Cr |
| 3 Oct 2022 | Buy · block | ISHARES MSCI INDIA SMALL-CAP ETF | 6.4K | 4,106.95 | ₹2.6Cr |
| 13 Jan 2014 | Buy · bulk | RELIANCE MUTUAL FUND A/C RELIANCE PHARMA FUND · as MERCK | 2.56L | 549.00 | ₹14.1Cr |
| 13 Jan 2014 | Sell · bulk | AMERICAN FUND INSURANCE A/C AMERICAN INSURANCE SERIES GLOBAL · as MERCK | 1.42L | 549.00 | ₹7.8Cr |
| 13 Jan 2014 | Sell · bulk | SMALLER CAP WORLD FUND INC · as MERCK | 1.14L | 549.00 | ₹6.3Cr |
A bulk deal is a client trading over 0.5% of the company’s shares in a day; a block deal is one large trade in the separate block window. Quantities and prices are as NSE published them, not split-adjusted.
Takeover-code disclosures
Filed under SEBI’s takeover regulations when a holding crosses 5% of the company, and again with every 2% it moves after that. Shares and percentages as filed.
Every stock on this session →Short selling, lending & margin
Shares sold short on the day, as brokers reported them to NSE at the close. As reported, not split-adjusted.
Exchange surveillance
No surveillance measure applies to PGHL.
Price band: 20% · not in the F&O ban.
From NSE’s daily surveillance, price-band and position-limit files. A stock enters the F&O ban when open interest passes 95% of its market-wide position limit and leaves it below 80%; until then no new positions can be opened. CSV: band changes.
Every stock on this session →Financials · quarterly statement
| Q3 FY24 | Q4 FY24 | Q1 FY25A | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Q2 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 310.0 | 252.5 | 283.9 | 313.4 | 309.8 | 311.0 | 338.7 | 324.9 | 373.9 | 370.5 | 363.7 | 382.5 | |
| Other income | 5.2 | 2.3 | 2.1 | 3.3 | 4.0 | 3.1 | 4.0 | 5.0 | 4.4 | 4.0 | 3.9 | 3.9 | |
| Total income | 315.2 | 254.8 | 286.0 | 316.7 | 313.7 | 314.1 | 342.8 | 329.9 | 378.2 | 374.5 | 367.6 | 386.4 | |
| Total expenses | 215.4 | 192.0 | 243.0 | 205.3 | 192.0 | 235.6 | 254.0 | 210.9 | 269.4 | 241.2 | 270.3 | 236.3 | |
| └ Finance costs | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | |
| └ Depreciation | 6.9 | 6.8 | 7.2 | 5.8 | 5.6 | 5.4 | 5.4 | 6.1 | 5.9 | 6.2 | 6.0 | 6.1 | |
| Profit before tax | 99.7 | 62.7 | 22.8 | 111.4 | 121.7 | 78.5 | 88.8 | 119.0 | 108.8 | 133.2 | 129.1 | 150.1 | |
| Tax expense | 27.7 | 16.2 | 6.1 | 29.1 | 30.8 | 17.4 | 22.6 | 30.5 | 31.2 | 38.6 | 33.0 | 38.5 | |
| Net profit | 72.1 | 46.6 | 16.8 | 82.3 | 90.9 | 61.2 | 66.2 | 88.5 | 77.6 | 94.6 | 96.2 | 111.5 | |
| EPS | 43.40 | 28.00 | 10.11 | 49.60 | 54.76 | 36.86 | 39.87 | 53.34 | 46.74 | 56.99 | 57.92 | 67.18 | |
| Net margin | 23.25% | 18.44% | 5.91% | 26.27% | 29.34% | 19.67% | 19.54% | 27.25% | 20.75% | 25.54% | 26.44% | 29.15% | |
| PBT margin | 32.17% | 24.84% | 8.04% | 35.54% | 39.28% | 25.25% | 26.22% | 36.63% | 29.11% | 35.96% | 35.50% | 39.23% | |
| Tax rate | 27.73% | 25.77% | 26.50% | 26.10% | 25.30% | 22.09% | 25.48% | 25.61% | 28.70% | 28.98% | 25.53% | 25.68% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. The balance sheet and cash flow arrive only with the half-year and annual filings, and are in their own section below. Latest filed 2 Nov 2026.
Balance sheet & cash flow · half-yearly
Balance sheet
| Q1 FY24 | Q3 FY24 | Q1 FY25 | Q3 FY25 | FY25 | H1 FY26 | FY26 | H1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1,101.2 | 1,077.1 | 794.4 | 870.2 | 794.2 | 894.4 | 841.4 | 1,014.6 | |
| Current assets | 796.1 | 771.3 | 515.2 | 611.4 | 526.4 | 638.2 | 556.3 | 720.1 | |
| └ Cash & equivalents | 435.1 | 420.6 | 238.5 | 266.4 | 182.1 | 279.3 | 177.2 | 322.9 | |
| └ Other bank balances | 5.2 | 5.0 | 5.9 | 6.3 | 6.5 | 6.9 | 8.1 | 6.2 | |
| └ Current investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| └ Trade receivables | 115.7 | 135.8 | 85.3 | 130.7 | 145.4 | 137.5 | 164.3 | 175.8 | |
| └ Inventories | 134.9 | 129.1 | 109.1 | 118.8 | 109.4 | 127.3 | 136.7 | 136.9 | |
| Total equity | 750.9 | 805.9 | 538.2 | 610.5 | 537.0 | 619.7 | 524.6 | 658.1 | |
| └ Attributable to owners | 750.9 | 805.9 | 538.2 | 610.5 | 537.0 | 619.7 | 524.6 | 658.1 | |
| └ Share capital | 16.6 | 16.6 | 16.6 | 16.6 | 16.6 | 16.6 | 16.6 | 16.6 | |
| Borrowings | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| └ Current | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| └ Non-current | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Trade payables | 237.0 | 171.6 | 167.0 | 171.4 | 171.6 | 175.3 | 192.2 | 231.0 | |
| Current liabilities | 303.9 | 230.5 | 218.9 | 219.9 | 215.3 | 222.5 | 254.9 | 296.9 | |
| Total liabilities | 350.3 | 271.2 | 256.1 | 259.7 | 257.2 | 274.7 | 316.8 | 356.5 | |
| Net debt | (440.2) | (425.6) | (244.4) | (272.7) | (188.6) | (286.2) | (185.3) | (329.0) | |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Current ratio | 2.62 | 3.35 | 2.35 | 2.78 | 2.44 | 2.87 | 2.18 | 2.43 |
Cash flow, year to date
| Q1 FY24 | Q3 FY24 | Q1 FY25 | Q3 FY25 | 9M to FY25 | H1 FY26 | FY26 | H1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 236.0 | 74.6 | 228.3 | 119.5 | 168.7 | 172.2 | 337.8 | 190.9 | |
| └ Capex | (42.5) | (15.0) | (21.7) | (5.3) | 0.0 | (6.0) | (15.5) | (9.7) | |
| Free cash flow | 193.5 | 59.6 | 206.6 | 114.1 | 168.7 | 166.2 | 322.3 | 181.2 | |
| Investing cash flow | (21.5) | (4.5) | (6.9) | 9.6 | 9.6 | 1.4 | 1.3 | 31.7 | |
| Financing cash flow | (98.5) | (84.6) | (418.1) | (101.2) | (234.7) | (76.4) | (343.9) | (77.0) | |
| └ Dividends paid | (93.8) | (83.0) | (415.0) | (99.6) | (232.4) | (74.7) | (340.3) | (74.7) | |
| └ Buybacks | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Net change in cash | 116.0 | (14.5) | (196.7) | 28.0 | (56.5) | 97.3 | (4.9) | 145.6 |
From the half-year and annual results filings: the balance sheet from September 2022, the cash flow from September 2020. Those are when NSE’s XBRL began to carry each statement; earlier filings have it only in the attached PDF. Cash flow columns are year to date, so an H1 column covers April to September and an FY column the full year. Outflows are in parentheses. Net debt is borrowings less cash, bank balances and current investments; for banks, NBFCs and insurers it, debt to equity and the current ratio are left blank because their statements are not built that way.
Announcements & board meetings
As the company filed them with NSE, newest first. Board meetings are dated by the meeting, which is usually a week or more after the intimation.
Every stock on this session →PGHL at a glance
- PGHL closed at ₹5,589.5 on 20 Nov 2026, +0.96% on the day, -5.1% over one year, 19.9% below its 52-week high of ₹6,975.
- Delivery was 58.1% of traded quantity on 20 Nov 2026, the 41st percentile of its own 3,629 sessions with a reading (20-session average 51.8%, 1-year average 59.0%).
- Market capitalisation is ₹9,278 crore at a trailing P/E of 24.4 (trailing EPS ₹228.83).
- Q2 FY27 results (standalone, filed 2 Nov 2026): revenue ₹382 crore (+17.7% year on year), net profit ₹112 crore (+25.9%); the price moved +0.5% on the first session after.
- Promoters held 51.82% at 30 Sept 2026, unchanged on the previous filing.
- Q3 FY27 results are expected between 6 Feb 2027 and 12 Feb 2027, going by past filing dates — an estimate, not an announcement.
About
Sector history
- to 5 Oct 2026Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
- from 5 Oct 2026Index industry · Healthcare
NSE’s own classification, by the snapshot it changed on.
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 20 Nov 2026.
More in Pharmaceuticals & Biotechnology
- DIDIVISLABDivi's Laboratories Limited11,180.50+0.02%
- LALAURUSLABSLaurus Labs Limited2,294.60-0.49%
- SUSUNPHARMASun Pharmaceutical Industries Limited1,884.90-0.79%
- ACACUTAASAcutaas Chemicals Limited3,833.50-3.61%
- SASAILIFESai Life Sciences Limited1,800.70+0.69%
- PPPPLPHARMAPiramal Pharma Limited239.30-0.15%
- DRDRREDDYDr. Reddy's Laboratories Limited1,390.20-0.76%
- GLGLENMARKGlenmark Pharmaceuticals Limited2,648.00+1.51%
- AUAUROPHARMAAurobindo Pharma Limited1,799.00-0.37%
- CICIPLACipla Limited1,415.00-0.25%
- ZYZYDUSLIFEZydus Lifesciences Limited1,200.00-0.24%
- MAMANKINDMankind Pharma Limited2,665.00+1.37%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE